FOLH1 and neoplasm: In both cases, the radiopharmaceutical showed specific uptake in PSMA(+) cancerous tissue, sufficient tumour uptake up to 24 h p.i. (10.58 ± 4.50%ID/g) and rapid renal clearance [92,95].